All In Biotech

Drug Trial Radar · NCT03660800

Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy Subjects

An Open-label, Single-Dose, Safety, Tolerability and Pharmacokinetic Study of Oral CTAP101 (Calcifediol) Extended-release Capsules in Japanese and Non-Japanese Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Sep 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

67

Actual

Start

Aug 20, 2018

Primary completion

Oct 24, 2018

Study completion Jan 22, 2019

Sponsor

Lead sponsor
OPKO Health, Inc.Industry
Sponsor type
Industry
First posted
Sep 7, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and non-Japanese Healthy Subjects

Conditions

  • Vitamin D Insufficiency
  • Secondary Hyperparathyroidism

Interventions

  • CTAP101 CapsulesDrug

    Calcifediol Extended-Release Capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-related AEs as assessed by industry standardsTime frame: 8 weeks
  2. Change in baseline of peak plasma concentrationTime frame: 8 weeks
  3. Change in mean total of the different components of calcifediolTime frame: 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • WCCT Global, Inc.

    Cypress, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.